Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
MNOV's Cash to Debt is ranked higher than
97% of the 1484 Companies
in the Global Biotechnology industry.

( Industry Median: 48.31 vs. MNOV: No Debt )
MNOV' s 10-Year Cash to Debt Range
Min: 0.67   Max: No Debt
Current: No Debt

F-Score: 2
Z-Score: -4.78
M-Score: -3.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -38.58
MNOV's ROE (%) is ranked higher than
68% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: -28.35 vs. MNOV: -38.58 )
MNOV' s 10-Year ROE (%) Range
Min: -788.84   Max: -19.99
Current: -38.58

-788.84
-19.99
ROA (%) -32.05
MNOV's ROA (%) is ranked higher than
68% of the 1489 Companies
in the Global Biotechnology industry.

( Industry Median: -22.44 vs. MNOV: -32.05 )
MNOV' s 10-Year ROA (%) Range
Min: -172.07   Max: -16.41
Current: -32.05

-172.07
-16.41
ROC (Joel Greenblatt) (%) -4260.09
MNOV's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 1448 Companies
in the Global Biotechnology industry.

( Industry Median: -352.58 vs. MNOV: -4260.09 )
MNOV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -39131.25   Max: -108.93
Current: -4260.09

-39131.25
-108.93
EBITDA Growth (3Y)(%) -29.60
MNOV's EBITDA Growth (3Y)(%) is ranked higher than
60% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. MNOV: -29.60 )
MNOV' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -83.3   Max: 188.9
Current: -29.6

-83.3
188.9
EPS Growth (3Y)(%) -31.80
MNOV's EPS Growth (3Y)(%) is ranked higher than
60% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. MNOV: -31.80 )
MNOV' s 10-Year EPS Growth (3Y)(%) Range
Min: -86.2   Max: 254
Current: -31.8

-86.2
254
» MNOV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

MNOV Guru Trades in

Q3 2014

MNOV Guru Trades in Q3 2014

Jim Simons 49,400 sh (New)
» More
Q4 2014

MNOV Guru Trades in Q4 2014

Jim Simons 115,800 sh (+134.41%)
» More
Q1 2015

MNOV Guru Trades in Q1 2015

Jim Simons 110,800 sh (-4.32%)
» More
» Details

Insider Trades

Latest Guru Trades with MNOV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.00
MNOV's P/B is ranked higher than
69% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. MNOV: 5.00 )
MNOV' s 10-Year P/B Range
Min: 0.18   Max: 5
Current: 5

0.18
5
EV-to-EBIT -9.52
MNOV's EV-to-EBIT is ranked higher than
87% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MNOV: -9.52 )
MNOV' s 10-Year EV-to-EBIT Range
Min: -28   Max: 1.6
Current: -9.52

-28
1.6
Current Ratio 12.12
MNOV's Current Ratio is ranked higher than
89% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. MNOV: 12.12 )
MNOV' s 10-Year Current Ratio Range
Min: 1.31   Max: 49.29
Current: 12.12

1.31
49.29
Quick Ratio 12.12
MNOV's Quick Ratio is ranked higher than
90% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. MNOV: 12.12 )
MNOV' s 10-Year Quick Ratio Range
Min: 1.31   Max: 49.29
Current: 12.12

1.31
49.29

Valuation & Return

vs
industry
vs
history
Price/Net Cash 22.50
MNOV's Price/Net Cash is ranked higher than
70% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 220.30 vs. MNOV: 22.50 )
MNOV' s 10-Year Price/Net Cash Range
Min: 0.71   Max: 30.33
Current: 22.5

0.71
30.33
Price/Net Current Asset Value 22.50
MNOV's Price/Net Current Asset Value is ranked higher than
68% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 46.00 vs. MNOV: 22.50 )
MNOV' s 10-Year Price/Net Current Asset Value Range
Min: 0.69   Max: 20.22
Current: 22.5

0.69
20.22
Price/Tangible Book 15.00
MNOV's Price/Tangible Book is ranked higher than
53% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 10.40 vs. MNOV: 15.00 )
MNOV' s 10-Year Price/Tangible Book Range
Min: 0.4   Max: 54.67
Current: 15

0.4
54.67
Earnings Yield (Greenblatt) -10.40
MNOV's Earnings Yield (Greenblatt) is ranked higher than
57% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. MNOV: -10.40 )
MNOV' s 10-Year Earnings Yield (Greenblatt) Range
Min: -10.6   Max: 8448.3
Current: -10.4

-10.6
8448.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NONOF, AMGN, GILD, BIIB, CELG » details
Traded in other countries:4875.Japan, RMN.Germany,
MediciNova Inc was incorporated in the State of Delaware on September 2000.It is a biopharmaceutical company focused on developing novel, small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the U.S. market. The Company operates in a single industry segment - the discovery and development of small molecule therapeutics. Its core program includes, MN-001 (NASH), MN-166 (Neurology Diseases) and MN-221 (Respiratory Diseases). Its non-core programs include, MN-001 (Bronchial Asthma), MN-001 (Interstitial Cystitis), MN-029 (Cancer) and MN-221 (Preterm Labor). The Company is subject to government regulations, in the U.S., the FDA, under the Federal Food, Drug and Cosmetic Act, as amended, and other federal statutes and regulations.
» More Articles for MNOV

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... May 22 2015
MEDICINOVA INC Financials May 16 2015
10-Q for MediciNova, Inc. May 13 2015
MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure May 12 2015
MEDICINOVA INC Files SEC form 10-Q, Quarterly Report May 11 2015
MediciNova Announces Full Enrollment in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS May 07 2015
MediciNova Announces Full Enrollment in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS May 07 2015
MNOV: MediciNova's Deep Pipeline Is Meaningfully Undervalued May 06 2015
10-K for MediciNova, Inc. May 05 2015
MEDICINOVA INC Files SEC form 8-K, Change in Directors or Principal Officers Apr 29 2015
Baseline Characteristics of 228 Subjects Enrolled in MediciNova's Phase 2b Trial of MN-166... Apr 23 2015
Baseline Characteristics of 228 Subjects Enrolled in MediciNova's Phase 2b Trial of MN-166... Apr 23 2015
MediciNova Announces Positive Interim Safety Data From Clinical Trial of MN-166 (ibudilast) in ALS Apr 21 2015
MediciNova Announces Positive Interim Safety Data From Clinical Trial of MN-166 (ibudilast) in ALS Apr 21 2015
MedicNova (MNOV) Stock is Gaining Today After Drug Receives Fast Track Designation Apr 16 2015
Tokyo Stock Exchange Announces New Rule Affecting Trading of MediciNova Stock in Japan Apr 16 2015
Tokyo Stock Exchange Announces New Rule Affecting Trading of MediciNova Stock in Japan Apr 16 2015
FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of NASH... Apr 16 2015
FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of NASH... Apr 16 2015
MEDICINOVA INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Apr 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK